Grand River Aseptic Manufacturing Announces Majority Investment by Arlington Capital Partners

08:00 EST 14 Nov 2017 | Businesswire

This article has expired, however you can still download the PDF.
Grand River Aseptic Manufacturing (GRAM), a leading provider of high-quality, sterile parenteral solutions, has a new majority owner: Arlington Capital Partners, a private equity firm in the Washington, D.C., area. Among ...

Other Sources for this Article

Grand River Aseptic Manufacturing
Val Dittrich, 616-678-2400 x210


More From BioPortfolio on "Grand River Aseptic Manufacturing Announces Majority Investment by Arlington Capital Partners"

Quick Search


Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...